MedTrace Logo

Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

NCT03652376 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-08-29

No results posted yet for this study

Summary

This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.

Conditions

  • Severe Eosinophilic Asthma

Interventions

DRUG

Benralizumab

Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)

Sponsors & Collaborators

  • University of Rostock

    lead OTHER

Principal Investigators

  • Marek Lommatzsch, MD · University of Rostock

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-05-01
Completion
2019-12-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652376 on ClinicalTrials.gov